Srisathya Srinivasan

Srisathya Srinivasan

Auto-generated profile, based on publicly available information

Srisathya Srinivasan

Department of Cell Biology and Human Anatomy, University of California, Davis School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SSSara E. Konopelski Snavely
Sara E. Konopelski Snavely
MSMichael W. Susman
Michael W. Susman
RKRyan C. Kunz
Ryan C. Kunz
JTJia Tan
Jia Tan
SSSrisathya Srinivasan
Srisathya Srinivasan
HHHsin-Yi Ho
Hsin-Yi Ho
Wnt5a-Ror signaling is a conserved pathway that regulates morphogenetic processes during vertebrate development [R. T. Moon et al., Development 119, 97–111 (1993); I. Oishi et al., Genes Cells 8, 645–654 (2003)], but its downstream signaling events remain poorly understood. Through a large-scale proteomic screen in mouse embryonic fibroblasts, we identified the E3 ubiquitin ligase Pdzrn3 as a regulatory target of the Wnt5a-Ror pathway. Upon pathway activation, Pdzrn3 is degraded in a β-catenin–independent, ubiquitin-proteasome system–dependent manner. We developed a flow cytometry-based reporter to monitor Pdzrn3 abundance and delineated a signaling cascade involving Frizzled, Dishevelled, Casein kinase 1, and Glycogen synthase kinase 3 that regulates Pdzrn3 stability. Epistatically, Pdzrn3 is regulated independently of Kif26b, another Wnt5a-Ror effector. Wnt5a-dependent degradation of Pdzrn3 requires phosphorylation of three conserved amino acids within its C-terminal LNX3H domain [M. Flynn, O. Saha, P. Young, BMC Evol. Biol. 11, 235 (2011)], which acts as a bona fide Wnt5a-responsive element. Importantly, this phospho-dependent degradation is essential for Wnt5a-Ror modulation of cell migration. Collectively, this work establishes a Wnt5a-Ror cell morphogenetic cascade involving Pdzrn3 phosphorylation and degradation. Significance Wnt5a-Ror signaling is a master regulator of tissue shape, and dysfunction of the pathway contributes to congenital birth defects and cancer metastasis. The molecular underpinnings of this pathway, however, remain unclear. To identify subcellular protein changes driven by Wnt5a-Ror signaling, we conducted a large-scale proteomic screen and identified the E3 ubiquitin ligase Pdzrn3 as a downstream target. Wnt5a-Ror signaling initially induces Pdzrn3 phosphorylation, which subsequently triggers the ubiquitin-proteasome–dependent degradation of Pdzrn3. Importantly, Wnt5a-Ror signaling uses this phospho-degradation process to regulate cell migration. From these findings, we further developed a flow cytometry-based reporter to monitor Pdzrn3 abundance and delineated the signaling cascade regulating Pdzrn3 stability. Collectively, our study establishes Pdzrn3 phosphorylation and degradation as a key component of Wnt5a-Ror signaling.

25 February 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ADAlka Dwivedi
Alka Dwivedi
AKAtharva Karulkar
Atharva Karulkar
SGSarbari Ghosh
Sarbari Ghosh
SSSrisathya Srinivasan
Srisathya Srinivasan
Bajarang Vasant KumbharBajarang Vasant Kumbhar
Bajarang Vasant Kumbhar
RPRahul Purwar
Rahul Purwar
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of patients develop life-threatening toxicities associated with cytokine release syndrome which may limit its utilization in low-resource settings. To mitigate the toxicity, we designed a novel humanized anti-CD19 CAR T cells by humanizing the framework region of single-chain variable fragment (scFv) derived from a murine FMC63 mAb and combining it with CD8α transmembrane domain, 4-1BB costimulatory domain, and CD3ζ signaling domain (h1CAR19-8BBζ). Docking studies followed by molecular dynamics simulation revealed that the humanized anti-CD19 scFv (h1CAR19) establishes higher binding affinity and has a flexible molecular structure with CD19 antigen compared with murine scFv (mCAR19). Ex vivo studies with CAR T cells generated from healthy donors and patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) expressing either h1CAR19 or mCAR19 showed comparable antitumor activity and proliferation. More importantly, h1CAR19-8BBζ T cells produced lower levels of cytokines (IFNγ, TNFα) upon antigen encounter and reduced the induction of IL6 cytokine from monocytes than mCAR19-8BBζ T cells. There was a comparable proliferation of h1CAR19-8BBζ T cells and mCAR19-8BBζ T cells upon repeated antigen encounter. Finally, h1CAR19-8BBζ T cells efficiently eliminated NALM6 tumor cells in a preclinical model. In conclusion, the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity providing a rationale to test this construct in a phase I trial.

23 May 2024 in eLife
Verified
Journal Article
Open access
SGSamuel C Griffiths
Samuel C Griffiths
JTJia Tan
Jia Tan
Armin WagnerArmin Wagner
Armin Wagner
LBLevi L Blazer
Levi L Blazer
JAJarrett J Adams
Jarrett J Adams
HHHsin-Yi Ho
Hsin-Yi Ho
The receptor tyrosine kinase ROR2 mediates noncanonical WNT5A signaling to orchestrate tissue morphogenetic processes, and dysfunction of the pathway causes Robinow syndrome, brachydactyly B, and metastatic diseases. The domain(s) and mechanisms required for ROR2 function, however, remain unclear. We solved the crystal structure of the extracellular cysteine-rich (CRD) and Kringle (Kr) domains of ROR2 and found that, unlike other CRDs, the ROR2 CRD lacks the signature hydrophobic pocket that binds lipids/lipid-modified proteins, such as WNTs, suggesting a novel mechanism of ligand reception. Functionally, we showed that the ROR2 CRD, but not other domains, is required and minimally sufficient to promote WNT5A signaling, and Robinow mutations in the CRD and the adjacent Kr impair ROR2 secretion and function. Moreover, using function-activating and -perturbing antibodies against the Frizzled (FZ) family of WNT receptors, we demonstrate the involvement of FZ in WNT5A-ROR signaling. Thus, ROR2 acts via its CRD to potentiate the function of a receptor super-complex that includes FZ to transduce WNT5A signals.

1 June 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SDSreya Das
Sreya Das
VSVishakha Surve
Vishakha Surve
SMSoumitra Marathe
Soumitra Marathe
SWSiddhi Wad
Siddhi Wad
AKAtharva Karulkar
Atharva Karulkar
RPRahul Purwar
Rahul Purwar
IL-9 is produced by Th9 cells and is classically known as a growth-promoting cytokine. Although protumorigenic functions of IL-9 are described in T cell lymphoma, recently, we and others have reported anti-tumor activities of IL-9 in melanoma mediated by mast cells and CD8+ T cells. However, involvement of IL-9 in invasive breast and cervical cancer remains unexplored. In this study, we demonstrate IL-9–dependent inhibition of metastasis of both human breast (MDA-MB-231 and MCF-7) and cervical (HeLa) tumor cells in physiological three-dimensional invasion assays. To dissect underlying mechanisms of IL-9–mediated suppression of invasion, we analyzed IL-9–dependent pathways of cancer cell metastasis, including proteolysis, contractility, and focal adhesion dynamics. IL-9 markedly blocked tumor cell–collagen degradation, highlighting the effects of IL-9 on extracellular matrix remodeling. Moreover, IL-9 significantly reduced phosphorylation of myosin L chain and resultant actomyosin contractility and also increased focal adhesion formation. Finally, IL-9 suppressed IL-17– and IFN-γ–induced metastasis of both human breast (MDA-MB-231) and cervical (HeLa) cancer cells. In conclusion, IL-9 inhibits the metastatic potential of breast and cervical cancer cells by controlling extracellular matrix remodeling and cellular contractility. Key Points IL-9 inhibits breast and cervical cancer cell migration in a 3D experimental system. IL-9 reduces ECM remodeling capability and cellular contractility. IL-9 suppresses IL-17– and IFN-γ–mediated metastasis of cancer cells.

30 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSrisathya Srinivasan
Srisathya Srinivasan
HHHsin-Yi Ho
Hsin-Yi Ho
Mouse embryonic fibroblasts (MEFs) derived from genetically modified mice are a valuable resource for studying gene function and regulation. The MEF system can also be combined with rescue studies to characterize the function of mutant genes/proteins, such as disease-causing variants. However, primary MEFs undergo senescence soon after isolation and passaging, making long-term genetic manipulations difficult. Previously described methods for MEF immortalization are often inefficient or alter the physiological properties of the cells. Here, we describe an optimized protocol for immortalizing MEFs via CRISPR-mediated deletion of the Tp53 gene. This method is highly efficient and consistently generates immortalized MEFs, or iMEFs, within 14 days. Importantly, iMEFs closely resemble the parent cell populations, and individual iMEFs can be cloned and expanded for subsequent genetic manipulation and characterization. We envision that this protocol can be adopted to immortalize other mouse primary cell types. Key Features: CRISPR-based knockout of the Tp53 gene enables efficient immortalization of mouse embryonic fibroblasts (MEFs) in under 2 weeks. Immortalization requires a Neon electroporator or another comparable electroporation system to transfect cells with the Tp53 CRISPR constructs.